Advances in Lipid-Lowering Therapy in Atherosclerosis
- 1 January 2001
- book chapter
- Published by Springer Nature
- Vol. 498, 49-58
- https://doi.org/10.1007/978-1-4615-1321-6_8
Abstract
The treatment of atherosclerosis using lipid-lowering drugs has evolved markedly over the past decade. It has been driven by the results and implications of major clinical trials. There has been a paradigm shift in the last decade from stable coronary lesions of high-grade stenosis to unstable plaques of low-grade stenosis. These vulnerable culprit lesions are characterized by a large lipid core, rich in foam cells with a thin fibrous cap, rich in activated macrophages and inflammatory cells, and poor in smooth muscle cells1,2. The majority of myocardial infarctions arise from these plaques. Whereas stable, high-grade lesions allow for collateral circulation networks to form, culprit lesions are prone to rupture, hemorrhage and cause thrombus formation. There has also been renewed interest in the important contribution of endothelial dysfunction to impair myocardial perfusion in coronary artery disease (CAD)3. An acetylcholine infusion in normal arteries induces an endothelial-derived, nitric oxide-mediated vasodilation. In the presence of cardiovascular risk factors (i.e., hypercholesterolemia, smoking, hypertension, diabetes)4 or CAD, intraarterial acetylcholine induces a vasoconstriction which is inhibited by L-arginine analogues such as L-NMMA (N ω-Nitroso-Mono-Methyl-Arginine). More attention is being given to the inflammatory component of atherosclerosis5, which is assessed by plasma measurement of inflammatory markers such as C-reactive protein (CRP)6, IL-67,8, or serum amyloid-A protein (SAA)9. Methods have been developed to measure local changes in heat produced by the inflammatory reaction over atherosclerotic plaques. Using a highly sensitive special thermography catheter, Stefanadis et al.10have shown a significant increase in thermal heterogeneity of human atherosclerotic plaques studied by intravascular ultrasound (IVUS) in arteries from patients with unstable angina or myocardial infarction, as compared to those of controls or of subjects with stable plaques. They observed a correlation between plasma levels of CRP and increase in heat differences between plaque areas and normal adjacent areas.Keywords
This publication has 76 references indexed in Scilit:
- Inhibition of proinflammatory cytokine production by pravastatinThe Lancet, 1999
- Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levelsAmerican Heart Journal, 1998
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Comparison of Bezafibrate Versus Lovastatin or Lowering Plasma Insulin, Fibrinogen, and Plasminogen Activator Inhibitor-1 Concentrations in Hyperlipemic Heart Transplant PatientsThe American Journal of Cardiology, 1997
- Triglycerides: a risk factor for coronary heart diseaseAtherosclerosis, 1996
- Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.Journal of Clinical Investigation, 1996
- The Kuopio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoprotems, and atherosclerotic progressionThe American Journal of Cardiology, 1995
- Dose-Response Relationships of Serum Lipid Measurements With the Extent of Coronary StenosisArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)The American Journal of Cardiology, 1993